No Data
No Data
Institutional Owners May Consider Drastic Measures as Altimmune, Inc.'s (NASDAQ:ALT) Recent US$56m Drop Adds to Long-term Losses
Jim Cramer on Altimmune, Inc. (ALT): 'Healthcare Is So Out Of Fashion'
Most Shorted Stocks on Wall Street Heading Into 2025: BYND, KSS, GRPN, and More
We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate
Weight-loss Drugs in 2025, Auto Industry Outlook: Market Domination
B.Riley Financial Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $20